Novel Approaches to Restore Pancreatic Beta-Cell Mass and Function

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Beta-cell dysfunction and death are central to type 2 diabetes mellitus (T2DM) pathogenesis.
• Current T2DM management aims to preserve or restore beta-cell mass and function, not just control blood glucose.

Purpose of the Study:

• To review current and novel therapeutic strategies for T2DM focused on beta-cell preservation and regeneration.
• To discuss the mechanisms of action for these strategies on beta-cell physiology and glycemic control.
• To explore the potential of N-methyl-D-aspartate receptor (NMDAR) antagonists as a new class of antidiabetic drugs.

Main Methods:

• Literature review of existing and emerging T2DM treatments.
• Analysis of studies on lifestyle interventions, conventional medications, bariatric surgery, and NMDAR antagonism.
• Discussion of the impact on beta-cell function, mass, and overall glycemic control.

Main Results:

• Conventional therapies do not halt T2DM progression.
• Bariatric surgery is effective but limited to specific patient groups.
• NMDAR antagonism presents a novel therapeutic avenue with potential benefits for beta-cell health.

Conclusions:

• Timely intervention is important, but not always essential, for beta-cell recovery.
• NMDAR antagonists warrant further investigation for T2DM treatment.
• Personalized therapies based on disease risk or subtype may improve future diabetes management.